Mizuho has adjusted its price target for MiMedx Group (MDXG, Financial), reducing it from $16 to $15 while maintaining an Outperform rating on the stock. This adjustment comes as part of the firm's first-quarter preview for the medical devices and diagnostics sector.
The decision to lower the price target takes into account several key concerns, including the impact of tariffs, the company's exposure to the Chinese market, and recent developments in procedure outlooks. Mizuho's move reflects a preemptive approach to these challenges as the quarter unfolds.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for MiMedx Group Inc (MDXG, Financial) is $13.50 with a high estimate of $16.00 and a low estimate of $12.00. The average target implies an upside of 98.53% from the current price of $6.80. More detailed estimate data can be found on the MiMedx Group Inc (MDXG) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, MiMedx Group Inc's (MDXG, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for MiMedx Group Inc (MDXG, Financial) in one year is $6.82, suggesting a upside of 0.29% from the current price of $6.8. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the MiMedx Group Inc (MDXG) Summary page.
